Celldex Seeks $90M, End Zone for Rindopepimut

Celldex Therapeutics Inc. upsized its underwritten public offering by pricing 12 million shares of common stock at $7.50 – less than a 2 percent discount to Tuesday's close and a 1 percent premium to Monday's close – to seek a $90 million raise rather than $75 million cited in a preliminary prospectus filed Monday with the SEC.